442 results about "Chemotherapy Drugs" patented technology

The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties. Methods for sensitizing a cell such as a cancer cell to the effects of a chemotherapy drug comprising sequentially delivering PLK-1 interfering RNA followed by the chemotherapy drug are also provided.

The invention provides a curcumin oral emulsion and injection, wherein the emulsion comprises curcumin, oil, emulsifying agent and water, the injection also contains isotonic agent. The invention also discloses the process for preparing the emulsion and its use in preparing medicaments for treating or preventing tumor, resisting tumor transfer, enhancing curative effects of chemotherapy drugs, reducing side effects of chemotherapy and improving immunity functions for tumor patients.

A method for increasing the target-specific toxicity of a drug is effected by pretargeting an enzyme to a mammalian target site, and then administering a cytotoxic drug known to act at the target site or a prodrug form thereof which is converted to the drug in situ, which drug is also detoxified to form an intermediate of lower toxicity using said mammal's ordinary metabolic processes, whereby the detoxified intermediate is reconverted to its more toxic form by the pretargeted enzyme and thus has enhanced cytotoxicity at the target site. Further enhancement can be achieved by pretargeting an enzyme which converts the prodrug to the cytotoxic drug at the target site. Kits for use with the method also are provided. The method and kits permit lower doses of cytotoxic agents, maximize target site activity and minimize systemic side effects.

IMDs and methods are provided for electroporation treatment of subcutaneous tumors. In some embodiments, IMDs of the present invention may store and introduce chemotherapy drugs into the body prior to electroporation therapy. High frequency stimulation of tissue in or around the tumor may also be provided to increase tissue temperature prior to electroporation therapy. Still further, delivery of the electroporation therapy may be synchronized with cardiac qRs complex to avoid impeding normal cardiac rhythm. Algorithms to suspend therapy in the event of edema may also be incorporated.

The invention provides an application of a type of berbamine derivatives and salts thereof in the preparation of drugs for the treatment of tumors, which is mainly applied in the preparation of the drugs for the prevention and treatment of nuclear transcription factor NF-kBp65 activity-related diseases and BCR/ABL transcription activity-related diseases. The drugs are combined and prepared by the compounds of the invention and one or more pharmaceutically acceptable excipients. The preparation forms comprise solid preparations, semi-solid preparations or liquid preparations. The type of berbamine derivatives and the salts thereof provided by the invention have broader and stronger anti-leukemia and anti-solid-tumor activity, the tumors proved to be sensitive are leukemia, multiple myeloma, liver cancer, osteosarcoma and breast cancer; the toxicity and the side effects are lighter. An in vitro cell culture system and animal experiments confirm that the berbamine derivatives and the salts thereof have no significant toxicity or side effects to the growth of normal human hematopoietic cells and experimental animals under the anti-tumor dosage, which are superior to the commonly used chemotherapy drugs.

The invention discloses a nanometer medicine particle. The nanometer medicine particle comprises a hydrophobic polymer, a single-layer lipid molecule, an amphipathy macromolecular compound, at least one chemotherapy drug attached to the hydrophobic polymer, and at least one near-infrared photothermal conversion agent, wherein the hydrophobic polymer, the at least one chemotherapy drug attached to the hydrophobic polymer, and the at least one near-infrared photothermal conversion agent form a hydrophobic core; the single-layer lipid molecule surrounds the surface of the hydrophobic core to form an intermediate layer; and the amphipathy macromolecular compound intersperses in the intermediate layer to form a shell. The invention also provides a preparation method of the nanometer medicine particle. The nanometer medicine particle can realize the combined treatment of thermotherapy and chemotherapy and has high biocompatibility; and the preparation method is simple, convenient and easy to carry out.

The invention belongs to the field of pharmaceutic preparations, and relates to a targeted ligand-PEG (polyethylene glycol)-cholesterol/tocopherol derivative, and a preparation method and an application of the derivative, in particular to an application of the derivative in a composite mechanism mediate tumor targeted drug delivery system. According to the derivative, the preparation method and the application, a drug delivery system consisting of the targeted ligand-PEG-cholesterol/tocopherol derivative with a targeting function, a long circulating function and a pH (power of hydrogen) sensitive function as a functional material, a cation liposome and a drug can simultaneously carry anticancer polypeptide and gene/chemotherapy drugs. According to the system, different drugs are jointly entrapped into the lipid nano drug delivery system and delivered into a targeted cell by utilizing a physicochemical property difference between components or by in-vivo specific targeted recognition, signal conduction blocking and pH triggering PEG chain breaking charge reversion methods, so that a targeted tumor therapeutic effect is improved. According to the derivative, the preparation method and the application, the advantages of the system in directional delivery, co-delivery and the like are proved by in-vivo and in-vitro activity evaluation, the anticancer activity is improved significantly, and definite synergic therapeutic and immunity effects are provided.

The invention relates to the field of medical technologies, in particular to a lipoic-acid-modified nanometer polypeptide carrier and a preparation method and application thereof.The lipoic-acid-modified nanometer polypeptide carrier is composed of arginine, histidine, lipoic acid and cysteine.A disulfide bond contained in lipoic acid is adopted for cross-linking, a formed polypeptide polymer can be rapidly degraded in cells and will not accumulate in the cells, and arginine and cysteine in polypeptide are in-vivo amino acid and are free of toxic and side effects to the human body.A CCK-8 cell proliferation test shows that the prepared nanometer carrier has low cell toxicity and meanwhile has good capacity of co-delivery of a gene and chemotherapy drugs; the nanometer carrier can specifically enhance the sensitivity of drug-resistant cells to the chemotherapy drugs in breast cancer drug-resistant treatment and promote apoptosis of breast cancer cells, and therefore becomes a targeted, efficient and low-toxicity nanoscale delivery system in breast cancer drug-resistant treatment.

The invention relates to a biological nanometer magnetic target anti-cancer drug, which is formed by coupled biological nanometer magnetic smalls and anti-cancer chemical drug. Wherein, the biological nanometer magnetic small is nanometer magnetic particle formed in magnetic bacterial cell, at 35-120nm diameter, while its main component is Fe3O4 or Fe3S4; single magnetic particle is packed by film; and the coupled anti-cancer chemical drug comprises chemotherapy drug, nucleic acid drug, radioactive nuclide or antibody drug. The invention also provides relative production that using physical adsorption couple or based on the active function group contained by smalls and anti-cancer drug, to select right coupler via chemical reaction to couple them. And the smalls has better bioavailability, less side effect, therefore, the anti-cancer drug can be accurately transmitted to ill part via external magnetic field, to reduce the contact between drug and normal organism., to realize target positioning treatment.

The invention relates to a hypoxia response polymer nanoparticle and application thereof. The method comprises the following steps: firstly crosslinking 4,4-diaminoazobenzene and terephthalaldehyde taken as monomers, so as to form a conjugated polymer link, loading a photosensitizer and chemotherapy drugs through noncovalent interaction, and then forming the hypoxia response polymer nanoparticle through a nanoprecipitation method. The hypoxia response polymer nanoparticle can successfully carry the photosensitizer and the chemotherapy drugs to tumor cells, and produce active oxygen during illumination, so as to realize tumor killing. Azo bonds contained in the nanoparticle can be degraded under the action of reductase in cells, and chemotherapy drug release is realized. In addition, cell hypoxia caused during a photodynamic therapy process can further improve drug release, and the hypoxia response polymer nanoparticle can properly realize excellent tumor therapy effect through combination therapy effect of photodynamic therapy and chemical therapy.

The preparation method of radiation-sensitive copolymer carrier for coating radiated nanoparticles and/or chemotherapy drugs includes forming a nanosphere by diselenide block copolymers and DSPE-PEG-biomarkers to coat chemotherapy drugs and/or radiated nanoparticles that can be released from the opened nanosphere by protons penetrating tissue during proton therapy. The treatment effect of proton therapy is enhanced by two ways of using the radiated nanoparticles released from an opened nanosphere to produce nuclear fission with the protons for releasing electrons to destroy cancer cells of tumor and the chemotherapy drugs released from the opened nanosphere for distributing among tissue to kill the cancer cells of the tumor.

The invention provides a photosensitive liposome carrying oxygen to enhance photodynamics, which is composed of phospholipids, cholesterol, long-circulation materials, hemoglobin, and chemotherapeutic drugs and/or photosensitizers, each component is dissolved in an organic solvent, and the Steam to form a thin film, then add oxyhemoglobin solution, or a mixed solution of photosensitizers and/or chemotherapeutic drugs and oxyhemoglobin, and hydrate to obtain a multilayer liposome solution, which is obtained by ultrasonication and purification. The liposome of the present invention can simultaneously carry oxygen, chemotherapeutic drugs and/or photosensitizers to the tumor site, alleviate the hypoxic state of tumor cells, improve the sensitivity of tumor cells to chemotherapeutic drugs, inhibit tumor growth and metastasis, and can also Under the irradiation of near-infrared light, the photosensitizer in the liposome generates more singlet oxygen, resulting in an enhanced photodynamic therapy effect. The loaded drug molecules are released to realize remote control of drug release.

The objective of the invention is to provide a traditional Chinese medicine granule for treating side effects on an alimentary canal after cancer chemotherapy and a preparation method thereof. The invention is characterized in that the granule is prepared from an active component, a binder and pharmaceutically acceptable adjuvant, and the active component is prepared from the traditional Chinese medicines consisting of 600 to 800 g of milkvetch root, 250 to 350 g of dwarf lilyturf tuber, 150 to 250 g of red ginseng, 150 to 250 g of white atractylodes rhizome fried with bran, 150 to 250 g of Poria cocos, 200 to 300 g of licorice, 200 to 300 g of radix scrophulariae, 200 to 300 g of Chinese angelica, 250 to 350 g of dark plum, 250 to 350 g of prepared pinellia tuber, 200 to 300 g of cablin patchouli herb, 200 to 300 g of dried orange peel and 200 to 300 g of curcuma rhizome. The granule is applicable to cancer patients who vomit or retch because of damage of both qi and yin and rising of stomach qi resulting from damage of the spleen and the stomach by anti-radiogenic cancer and chemotherapy drugs, and the granule can mitigate symptoms like no appetite, tiredness, hypodynamia, a red or light red tongue with little fluid and weak pulse.

The invention belongs to the field of pharmaceutical polymer materials, in particular to a degradable polyethyleneimine (PCFC-PEI) cross-linked polymer capable of transferring chemotherapy drugs and gene drugs simultaneously, a preparation method and an application thereof. The PCFC-PEI carrier is a novel carrier material obtained by coupling polycaprolactone poloxamer-polycaprolactone and the polyethyleneimine, wherein the poloxamer is triblock copolymer of polyethylene glycol-polypropylene glycol-polyethylene glycol, the molecular weight thereof is 1100-12500, and the molecular weight of polyethyleneimine section is 600-25000. The degradable polyethyleneimine cross-linked polymer can be used as a novel drug-release carrier, and can transfer the micromolecular chemotherapy drugs and genetherapy drugs simultaneously, thus having wide application prospect in the preparation of anti-tumor drugs.

System and method for loading the front line anticancer drug, doxorubicin (DOX) onto DNA-capped gold nanoparticles whose duplex DNA has been designed for specific DOX intercalation. Since each AuNP contains about 108 high affinity drug sites, this design allows for a high local DOX concentration on the particle. Drug binding was confirmed by monitoring the increase in DNA melting temperature, the shift in the plasmon resonance maximum, and the increase in the NP hydrodynamic radius as a function of [DOX]/[DNA] ratio. The feasibility of the nanoparticles as a drug delivery system was demonstrated by showing that particle-bound DOX could be transferred to a target DNA.

The invention relates to PLGA ultrasonic nano bubbles integrating ultrasonic imaging, drug delivery and gene therapy into a whole and a preparation method thereof. The preparation method comprises the following steps: preparing drug-loading nano bubbles loaded with a chemotherapy drug DOX, further modifying PLGA nano bubbles through PEI, adsorbing shRNA plasmids of MDR-1, thereby forming the composite nano bubbles. The nano bubbles have high drug loading rate and encapsulation efficiency, drug release has pH responsiveness, the loaded genes can be protected, expression of drug resistance genes MDR-1 is effectively silenced, the ultrasonic imaging capacity can be exerted, and the drugs and genes can be simultaneously and efficiently delivered to tumor locations to exert a synergistic effect.

The invention belongs to the field of genetic engineering and particularly relates to application of long non-coding RNA (Ribonucleic Acid) uc003hsl.1 in preparation of drugs for treating non-small cell lung cancer. The influence on the apoptosis, propagation, drug susceptibility and the like of non-small cell lung cancer cells is caused through changing the expression of the long non-coding RNA uc003hsl.1, so that through lowering the expression of the long non-coding RNA uc003hsl.1, the apoptosis of the non-small cell lung cancer cells can be promoted, the propagation of the non-small cell lung cancer cells can be inhibited, and the susceptibility to chemotherapy drugs of the non-small cell lung cancer cells can be enhanced.

The invention relates to a preparation method and application of a rare earth up-conversion light-operated drug-delivery nano-carrier. The preparation method comprises the following steps: with a variety of rare earth salts as raw materials, preparing a rare earth up-conversion nanoparticle through a solvothermal process; synthesizing meso-porous silicon via a template process and carrying out coating; connecting a silane reagent to the surface of a meso-porous silicon shell layer; and finally, embedding a drug into meso pores. The nano-carrier prepared in the invention has a targeted aggregation effect and can realize precise positioning at a tumor site. The nano-carrier has a light-operated release effect; the drug is stored in the nano-carrier under the condition of no external near infrared laser (with wavelength of 980 nm) irradiation; the chemotherapy drug can only be released when a near infrared excitation source irradiates tumor tissue; thus, precise, timed and quantitative release of the nano-carrier at a tumor site can be realized. The nano-carrier has a fluorescence imaging function, can realize visualization of chemotherapy process and has the advantages of simple operation, good applicability, low cost and good dispersibility in water.